Combination of oral STING agonist MSA-2 and anti-TGF-β/PD-L1 bispecific antibody YM101: a novel immune cocktail therapy for non-inflamed tumors
Ming Yi(Southwest Medical University), Kongming Wu(Shanxi Medical University), Mengke Niu(Zhejiang Chinese Medical University), Jing Zhang(Peking University), Yuze Wu(Hohai University), Pengfei Zhou(First Affiliated Hospital of Henan University of Traditional Chinese Medicine), Qian Chu(Tongji Hospital), Dechao Jiao(Zhengzhou University), Hong Ge(Zhengzhou University), Shuangli Zhu(Chinese Center For Disease Control and Prevention), Yongxiang Yan(Wuhan YZY Biopharma (China))
Cited by 178
Related Papers
Combination strategies with PD-1/PD-L1 blockade: current advances and future directions
|Molecular Cancer|2022|1.4k
Notch signaling pathway: architecture, disease, and therapeutics
|Signal Transduction and Targeted Therapy|2022|1k
Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment
|Molecular Cancer|2019|604
Myeloid-derived suppressor cells: an emerging target for anticancer immunotherapy
|Molecular Cancer|2022|458
Chimeric antigen receptor T cells: a novel therapy for solid tumors
|Journal of Hematology & Oncology|2017|306